Study claim: LitoZin significantly reduced joint discomfort after three weeks.
Published: Winther K, et al. A powder made from seeds and shells of a rose-hip subspecies (Rosa canina) reduces symptoms of knee and hip osteoarthritis: a randomized, double-blind, placebo-controlled clinical trial. Scand J Rheumatol. 2005 Jul-Aug; 34(4): 302-8.
Abstract: The aim of this study was to determine whether an herbal remedy made from a subspecies of rose hip (Rosa canina) might reduce symptoms of osteoarthritis and consumption of rescue medication in patients suffering from osteoarthritis.
Ninety-four patients with osteoarthritis of the hip or knee were enrolled in a randomised, placebo-controlled, double-blind crossover trial. Forty-seven patients were given 5g of the herbal remedy daily for three months and the remaining patients were given a placebo. The group initially treated with placebo was then changed to rose hip and vice versa for another three-month period.
Upon inclusion and after three weeks and three months of each treatment period, pain, stiffness, disability and global severity of the disease were scored on a Western Ontario and McMaster University (WOMAC) questionnaire. After three weeks of treatment, patients, if possible, were allowed to reduce their consumption of 'rescue medication.' Data were analysed on the basis of intention to treat.
Rose hip resulted in a significant reduction in WOMAC pain as compared to placebo, when testing after three weeks of treatment. The consumption of 'rescue medication' significantly declined as a result of active treatment.
WOMAC disability, stiffness and global assessment of severity of the disease were not altered by three weeks but decreased significantly after three months of treatment.
Potential Applications: The herbal remedy can alleviate symptoms of osteoarthritis and reduce the consumption of 'rescue medication.' EuroPharma has North American rights to LitoZin and is looking to partner with companies to market LitoZin in the US.
+1 920 406 6511
Study Claim: MSM improves pain and physical function in people with knee osteoarthritis when compared to placebo.
Published: Kim LS, et al. Efficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: a pilot clinical trial. Osteoarthritis Cartilage 2006; 14:286-94.
Abstract: Osteoarthritis (OA) is the most common form of arthritis and the second most common cause of long-term disability among middle-aged and older adults in the United States. Methylsulfonylmethane (MSM) is a popular dietary supplement used as a single agent and in combination with other nutrients, and purported to be beneficial for arthritis. However, there is paucity of evidence to support the use of MSM.
A randomised, double-blind, placebo-controlled trial was conducted. Fifty men and women, 40-76 years of age with knee OA pain were enrolled in an outpatient medical centre. Intervention was 3g MSM or placebo twice a day for 12 weeks (6g/day total).
Outcomes included the Western Ontario and McMaster University Osteoarthritis Index visual analogue scale (WOMAC), patient and physician global assessments (disease status, response to therapy), and SF-36 (overall health-related quality of life).
Compared to placebo, MSM produced significant decreases in WOMAC pain and physical function impairment (P
MSM (3g twice a day) improved symptoms of pain and physical function during the short intervention without major adverse events. The benefits and safety of MSM in managing OA and long-term use cannot be confirmed from this pilot trial, but its potential clinical application is examined.
Potential applications: OptiMSM by Cardinal Nutrition is available as uniform white microprills or flakes, suitable for tablets or capsules in joint-health supplements.
+1 888 733 5676